Roy F. Chemaly
Advanced in Sepsis

Dr. Roy F. Chemaly

Infectious Disease
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
29 Years of Experience
Advanced in Sepsis
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roy Chemaly is an Infectious Disease provider in Houston, Texas. Dr. Chemaly has been practicing medicine for over 29 years and is rated as an Advanced provider by MediFind in the treatment of Sepsis. His top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, Parainfluenza, and Febrile Neutropenia.

His clinical research consists of co-authoring 234 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 14 articles in the study of Sepsis.

Specialties
Infectious Disease
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts
Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts
Enrollment Status: Recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Baloxavir Marboxil, Oseltamivir
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: October 17, 2025
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Enrollment Status: Completed
Publish Date: February 09, 2023
Intervention Type: Diagnostic test
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia
A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia
Enrollment Status: Withdrawn
Publish Date: July 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 7 Less Clinical Trials

234 Total Publications

Corrigendum to 'American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients' [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016].
Corrigendum to 'American Society for Transplantation and Cellular Therapy Series #10: Management of Parainfluenza and Human Metapneumovirus Infections in Hematopoietic Cell Transplantation and Cellular Therapy Recipients' [Transplantation and Cellular Therapy 31 (2025) 624-638/ https://doi.org/10.1016/j.jtct.2025.06.016].
Journal: Transplantation and cellular therapy
Published: October 18, 2025
Similar Doctors
Cesar A. Arias
Distinguished in Sepsis
Dr. Cesar A. Arias
Infectious Disease | Anesthesiology
Distinguished in Sepsis
Dr. Cesar A. Arias
Infectious Disease | Anesthesiology

Tmh Physician Associates PLLC

6550 Fannin St, Suite 1101, 
Houston, TX 
 (0.6 miles away)
713-441-0006
Languages Spoken:
English
See accepted insurances

Cesar Arias is an Infectious Disease specialist and an Anesthesiologist in Houston, Texas. Dr. Arias is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Methicillin-Resistant Staphylococcus Aureus (MRSA), Endocarditis, Sepsis, and Pseudomonas Stutzeri Infections.

Distinguished in Sepsis
Dr. Muhammad R. Sohail
Infectious Disease
Distinguished in Sepsis
Dr. Muhammad R. Sohail
Infectious Disease

Baylor College Of Medicine

7200 Cambridge St, Fl 10, 
Houston, TX 
 (0.9 miles away)
713-798-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Muhammad Sohail is an Infectious Disease provider in Houston, Texas. Dr. Sohail is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Endocarditis, Sepsis, Infective Endocarditis, Thrombectomy, and Ureteral Reconstruction. Dr. Sohail is currently accepting new patients.

Distinguished in Sepsis
Dr. Bilal Sarvat
Infectious Disease
Distinguished in Sepsis
Dr. Bilal Sarvat
Infectious Disease
709 W Medical Ctr Blvd, 
Webster, TX 
 (20.4 miles away)
281-332-3322
Experience:
44+ years
Languages Spoken:
English
See accepted insurances

Bilal Sarvat is an Infectious Disease provider in Webster, Texas. Dr. Sarvat has been practicing medicine for over 44 years and is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Herpes Simplex Encephalitis, Pneumonia, and Necrotizing Fasciitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chemaly's expertise for a condition
ConditionClose
View All 9 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile